We are motivated to develop new therapies for severe diseases outside oncology by forming collaborative partnerships and piloting projects in new areas of science
Our strategic interactions are based on the ability of the platform to drug a wide variety of targets and allow us to tap into deep therapeutic expertise available within our partner organizations, enabling us to more efficiently develop novel medicines for patients.
Bicycle is collaborating in multiple disease areas outside oncology:
Respiratory & Cardiometabolic Disease
Leveraging the high bioavailability of Bicycles as topical inhaled agents, Bicycle has partnered with a world leader in respiratory science, AstraZeneca, to evaluate the potential for local delivery of inhaled Bicycles in the lung. In the same collaboration, AstraZeneca is evaluating Bicycles for the treatment of cardiovascular and metabolic diseases. AstraZeneca is using its therapy area expertise and access to significant resources to lead the optimisation of Bicycles identified by the Bicycle platform. In addition to the significant patient benefit that can result from leveraging the Bicycle technology in these diseases, Bicycle can receive >$1B in milestone payments in addition to single digit royalties should all products reach the market.
Rare non-malignant Haematology — Haemophilia and sickle cell disease
Due to their synthetic flexibility, tuneable PK characteristics and ability to generate high affinity, high selective binders to targets, Bicycles are ideal therapeutics for haematological disorders. To develop its new therapeutics based on bicyclic peptides for haemophilia and sickle cell disease, Bicycle has partnered with Bioverativ, the newly formed haematology-focused, spinout from Biogen. Under the collaboration, Bicycle will lead activities through to candidate selection, partnering with Bioverativ for therapeutic expertise. Bicycle received a $10 million upfront technology access fee and will also receive research funding, milestones and royalties from the collaboration.
Ophthalmology — Diabetic macular edema (DME)
The pharmacological and physicochemical characteristics of Bicycles also make them well suited for ophthalmology indications. Bicycle has partnered with leading ophthalmology company Thrombogenics for the development of novel plasma kallikrein inhibitors, including THR-149 for the treatment of diabetic macular edema. Clinical development of THR-149 is expected to begin in the first half of 2018. Bicycle receives milestones and royalty payments from the collaboration.
Bicycles are structurally similar to many of the commonly prescribed and highly effective natural product cyclic peptide antibiotics, making them ideal templates for the design of next generation antibacterial drugs. With the rapidly growing threat of antimicrobial resistance, new anti-infective products are urgently needed. Bicycle has secured a grant from Innovate UK, the UK’s innovation agency tasked with working with people, companies and partner organisations to identify and drive the science and technology innovations that will grow the UK economy, to apply Bicycle technology to develop the next generation of antibiotics. The Innovate UK funding will be used to develop Bicycles with unique properties and novel mechanisms of antibacterial action for the treatment of infectious diseases which will be led by Dr. Mike Dawson, the former CEO of Cantab Anti-infectives and an experienced antibiotic drug hunter.